Lucky Shire Pharmaceuticals.  The Irish drug-maker just had the popular ADHD drug, Vyvanse, approved as the first (and to date the only) treatment for the newly-recognized binge eating disorder.  For Shire's bottom line this could mean another $300 million a year in sales.  But prescribing Vyvanse to treat binge eating, NY Times investigative reporter Katie Thomas told KSFR's Dave Marash on HERE AND THERE, means putting millions of people on an addictive amphetamine. Shire was fined $56 million by the FDA for misleading advertising for Vyvanse as a treatment for ADHD, by overstating its effects and underrepresenting the risk of addiction.

Direct download: katiethomas.mp3
Category:KSFR News -- posted at: 1:11pm MDT

With only three days left in this year’s 60-day legislative session, we continue to feature the voices of people presenting and supporting bills being considered during this year’s session, focusing on their thoughts of this session and the legislation they still hope to see passed.

Direct download: voxpopz.mp3
Category:KSFR News -- posted at: 1:05pm MDT

By this time next year stalks of industrial hemp could be taking root in fields of New Mexico’s arid climate and small businesses that’ve been sowing the seeds of the industry could begin to turn a profit. As KSFR’s Deborah Martinez reports, a senate bill establishing state authority over industrial hemp faces one of the last hurdles before being sent to the governor’s desk for her signature.

Direct download: debmarhemp.mp3
Category:KSFR News -- posted at: 1:04pm MDT

KSFR's Kate Powell brings you local news at noon. 

Direct download: MARCH18NOONNEWS.mp3
Category:KSFR News -- posted at: 1:02pm MDT

Wednesday morning's top news stories from KSFR.

Direct download: 031815-First_News.mp3
Category:general -- posted at: 6:28am MDT